[Modern approach to WHO grade II glioma classification and treatment--review of the literature].
Although WHO grade II gliomas are slowly growing tumours, they inevitably show local recurrence and progression to higher grade counterparts. Progressive trials become time-consuming and troublesome because of relatively long survival and multimodal therapy. Recent discoveries in molecular pathology have divided patients into subgroups with different prognosis and expected response to therapy. Development did not omit surgical techniques, in particular intraoperative imaging and electrostimulation. The aim of radiotherapy development is preservation of the surroundings of the region of interest. Chemotherapy yields promising results notably with the possibility to choose patients with the best expected response. We present the current state of knowledge regarding these neoplasms.
Recławowicz
Daniel
D
Katedra i Klinika Neurochirurgii ACK Szpital AMG, ul. Dêbinki 7, 80-211 Gdañsk. daniel.r@amg.gda.pl
Stempniewicz
Mirosław
M
Biernat
Wojciech
W
Słoniewski
Paweł
P
D001932:Brain Neoplasms / Q000145:classification* / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005910:Glioma / Q000145:classification* / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D014944:World Health Organization